Transitional Cell Carcinoma — Trials

Transitional Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

734 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 253
Recruiting: 125
Ph III recruiting: 17
Growth YoY: +47.5%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 44%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (119)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05700227	Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer(ARTIA-Bladder)	terminated	N/A	2	Varian, a Siemens Healthineers CompanyINDUSTRY	1	Apr 21, 2026	clinicaltrials
NCT01495676	A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer(GETUGV04)	terminated	N/A	69	Institut du Cancer de Montpellier - Val d'Aurelle